Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

49.23 -0.13 (-0.26%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
72 73 Next >
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Bristol Myers Squibb Stock Is Sinking Today
Investors didn't like the biopharmaceutical company's updated guidance. 
Via The Motley Fool
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for... 
Via Benzinga
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal
Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024
BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb layoffs will see the company reduce its headcount by 6% as part of an effort to reduce expenses in 2024. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Is Bristol Myers Squibb Stock a Millionaire Maker?
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors. 
Via The Motley Fool
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
5 Crash-Proof Stocks to Buy Immediately
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
From Bristol Myers Squibb
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
These stocks pay between 3.2% and 6.7% in dividends. 
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels. 
Via The Motley Fool
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.